Literature DB >> 17002703

Differentiation of chronic sinus diseases by measurement of inflammatory mediators.

T Van Zele1, S Claeys, P Gevaert, G Van Maele, G Holtappels, P Van Cauwenberge, C Bachert.   

Abstract

BACKGROUND: Chronic rhinosinusitis (CRS) clinically is a heterogeneous group of sinus diseases, which may cover different disease entities, or may represent a disease continuum. Studying inflammatory cells and mediators in clearly defined disease subgroups may lead to a better differentiation of chronic sinus diseases.
METHODS: Sinonasal mucosal tissue from 10 nasal polyp (NP) patients, 13 cystic fibrosis patients (CF-NP), eight CRS subjects without polyps, and nine control patients were stained for CD3, CD25, CD68, CD20, myeloperoxidase (MPO), CD138 and tissue homogenates were assayed for eotaxin, interleukin (IL)-1beta, IL-2sRalpha, IL-5, interferon (IFN)-gamma, IL-8, transforming growth factor (TGF)-beta1, tumor necrosis factor-alpha, and MPO by enzyme-linked immunosorbent assay or UNICAP system.
RESULTS: Nasal polyp and CF-NP showed increased numbers and activation of T cells, while only NP displayed an increase in plasma cells. Nasal polyp had significantly higher levels of eosinophilic markers [eosinophils, eotaxin, and eosinophil cationic protein (ECP)] compared with CRS, controls and CF-NP. Chronic rhinosinusitis was characterized by a Th1 polarization with high levels of IFN-gamma and TGF-beta, while NP showed a Th2 polarization with high IL-5 and immunoglobulin (Ig) E concentrations. Nasal polyp and CF-NP were discriminated by edema from CRS and controls, with CF-NP displaying a very prominent neutrophilic inflammation.
CONCLUSION: Based on cellular and mediator profiles, we suggest that CRS, NP, and CF-NP are distinct disease entities within the group of chronic sinus diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17002703     DOI: 10.1111/j.1398-9995.2006.01225.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  228 in total

1.  [Rhinosinusitis guidelines--unabridged version: S2 guidelines from the German Society of Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; R Weber; K Hörmann
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

2.  Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Sarah Peterson; Julie A Poposki; Deepti R Nagarkar; Regina T Chustz; Anju T Peters; Lydia A Suh; Roderick Carter; James Norton; Kathleen E Harris; Leslie C Grammer; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  J Allergy Clin Immunol       Date:  2011-09-23       Impact factor: 10.793

3.  Myeloperoxydase expression in the pathogenesis of nasal polyps.

Authors:  Burcin A Sarisoy; Mehmet Eken; Alev Z Oktay; Mustafa Paksoy; Arif Sanli
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-04-13

Review 4.  Chronic rhinosinusitis management beyond intranasal steroids and saline solution irrigations.

Authors:  Newton Li; Anju T Peters
Journal:  Allergy Asthma Proc       Date:  2015 Sep-Oct       Impact factor: 2.587

5.  Chronic Rhinosinusitis: More Than Just "Asthma of the Upper Airway".

Authors:  Larry Borish
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

6.  IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps.

Authors:  Joanne L Shaw; Samer Fakhri; Martin J Citardi; Paul C Porter; David B Corry; Farrah Kheradmand; Yong-Jun Liu; Amber Luong
Journal:  Am J Respir Crit Care Med       Date:  2013-08-15       Impact factor: 21.405

Review 7.  Chronic Rhinosinusitis with Nasal Polyps.

Authors:  Whitney W Stevens; Robert P Schleimer; Robert C Kern
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Jul-Aug

Review 8.  Chronic Rhinosinusitis without Nasal Polyps.

Authors:  Seong Ho Cho; Dae Woo Kim; Philippe Gevaert
Journal:  J Allergy Clin Immunol Pract       Date:  2016 Jul-Aug

Review 9.  Antileukotrienes in upper airway inflammatory diseases.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Kagan Ipci; Ethem Şahin
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

Review 10.  Pathogenesis of nasal polyposis.

Authors:  K E Hulse; W W Stevens; B K Tan; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2015-02       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.